
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. presents a strong outlook due to its LIBERTY Endovascular Robotic System, which is designed to enhance procedure efficiency while significantly lowering costs and improving the quality of care in endovascular procedures. The company's estimated market value has reached $843 million, driven by a robust discounted cash flow-based asset value of $781 million for the LIBERTY System, indicating positive investor sentiment and confidence in future growth. Additionally, the firm has successfully raised sufficient capital to support its commercial strategy, and a remarkable 92% relative reduction in radiation exposure enhances the technology's appeal to healthcare providers.
Bears say
Microbot Medical Inc faces significant challenges that may hinder its growth potential, primarily due to slower than anticipated commercial uptake influenced by market size, penetration rates, and competitive pressures. Additionally, the company may encounter financial instability stemming from potential dilution risks, which could adversely affect shareholder value. These fundamental concerns contribute to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares